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Welcome!
Not loNg ago, the field of cancer immunology 
and immunotherapy (ie: harnessing the patient’s 
own immune system to fight cancer) was consid-
ered the “road to nowhere.” As an earlier member 
of a generation of “dreamers” and “truly believers” 
in this field, I was thrilled to learn this fall, that the 
Nobel Foundation in Stockholm presented the 2018 
Nobel Prize in Physiology or Medicine to two can-
cer immunotherapy pioneers, James P. Allison and 
Tasuku Honjo, “for their discovery of cancer therapy 
by inhibition of negative immune regulation.”
The rise to prominence for the rapidly expand-
ing scientific field is also gratifying news for the 
members of the George Washington University 
(GW) Cancer Center, as cancer immunology and 
immunotherapy research is a cornerstone of our 
basic science efforts — along with cancer biology 
(genetics, genomics, and epigenetics), microbial 
oncology, and cancer engineering. Together with 
our community outreach and engagement initia-
tives, cancer control, prevention and policy efforts 
and education, we are committed to rapidly move 
these areas of discovery to benefit the community 
we serve in Washington, D.C., and the surrounding 
counties. 
At the GW Cancer Center, we have many inves-
tigative teams pursuing immunological research to 
refine and develop this new generation of cancer 
therapies. By tapping into the body’s immune sys-
tem to fight disease, we are “re:discovering” that 
the cure is inside us. Although cancer immunother-
apy has been around for several decades, and after 
many failures, basic and translational investigations 
have begun to yield revolutionary results. 
Featured in this edition of re:discover is work 
by Catherine Bollard, MD, who has developed a 
new immunotherapy called TAA-T, which is a multi-
antigen specific T-cell product that appears to be 
superior in many ways and with less toxicity that the 
recently FDA-approved CAR T-cell therapy. Anoth-
er team of GW Cancer Center investigators, led by 
Rohan Fernandes, PhD, is integrating nanotechnol-
ogy with the immune response to achieve greater 
therapeutic results. They have re:discovered a use 
for nanoparticles found in a pigment once com-
monly used by the world’s great artists. Those tiny 
particles are super-heated to destroy previously 
inaccessible tumor tissue in the brain. And a third 
research team, led by Katherine Chiappinelli, PhD, 
is pouring through the body’s “junk DNA” to define 
the mechanisms controlling the immune signaling 
in cancer cells. By understanding how to increase 
the immune signaling coming from tumors, we can 
increase the number of immune cells in the tumors 
and make immunotherapies even more effective.
This basic and translational science research is 
a key facet of our comprehensive approach to can-
cer care. Projects such as these help to inform our 
clinical research enterprise, and those programs 
help to advance cancer care at every level. Reading 
these and other stories in the pages of re:discover, 
I hope you’ll agree that the new generation of sci-
entific “dreamers” and innovators we have brought 
together under the umbrella of GW Cancer Cen-
ter are well-poised to transform cancer care and, 
hopefully one of them will receive a phone call from 
Stockholm one cold morning in October. 
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Genetic Junk Is Too Good to Throw Away
lorieN 
abroms, scd, 
associate 
professor 
of prevention 
and commu-
nity health 
at the Milken 
Institute 
School of Pub-
lic Health at GW, has been named 
interim associate center director for 
population sciences and policy at the 
GW Cancer Center.
In this role, Abroms collaborates 
with faculty across GW to create a 
vision for the public health programs 
within the GW Cancer Center. She 
develops and manages initiatives 
to foster university-wide cancer re-
search collaborations among popula-
tion sciences and policy researchers.
Abroms is a behavioral scientist 
with expertise in applying communi-
cation technology to design scalable 
programs aimed at tobacco cessa-
tion. Her responsibilities also include 
identifying and nurturing the devel-
opment of program areas in cancer 
population sciences and policy, such 
as screening, environmental carcino-
gens, health care disparities, cancer 
epidemiology, and virus-related 
cancers such as HIV and HPV.
A Vision for 
Public Health
less thaN 3 perceNt of the DNA 
in our genome encodes proteins. 
Recent work has shown that a signifi-
cant part of the genome, initially con-
sidered “junk DNA,” does not code 
for proteins, but still has important 
biological functions, especially in 
cancer initiation and progression. A 
two-year, $300,000 grant from the G. 
Harold and Leila Y. Mathers Founda-
tion will help fund research led by 
Katherine Chiappinelli, PhD, assistant 
professor of microbiology, immunol-
ogy, and tropical medicine at SMHS, 
to define epigenetic determinants of 
repetitive element “junk DNA” con-
trol during tumor progression and 
lay the groundwork for understand-
ing interactions between these ele-
ments and the host immune system. 
The research project, titled “Epi-
genetic Modification and Expression 
of Retroelements in Cancer Develop-
ment,” includes a subcontract with 
Kathleen Helen Burns, MD, PhD, at 
Johns Hopkins Medicine, an expert 
in the field of repetitive elements in 
cancer. Repetitive elements are very 
different in cancer cells than they 
are in normal cells, but the medical 
community does not yet know which 
elements are affected and how they 
are altered as the cancer progresses. 
Outcomes of the project will include 
a more complete understanding of 
cancer progression and the identi-
fication of novel cancer therapeutic 
targets and/or biomarkers.
Chiappinelli and her colleagues 
will work to produce a compre-
hensive map of repetitive element 
regulation and expression during 
the progression of common tumors, 
including lung and ovarian cancer.
Survivorship 
e-Learning Series
the george WashiNgtoN UNi-
versity (gW) caNcer ceNter 
offers The Cancer Survivorship E-
Learning Series for Primary Care 
Providers (E-Learning Series), a 
free, self-paced continuing edu-
cation program for primary care 
providers interested in learning 
more about the needs of post-
treatment cancer survivors. 
The module-based, online 
format prepares physicians to 
care for, and attend to, the needs 
of cancer survivors by providing 
cancer specific guidelines for 
colorectal, breast, head and neck, 
and prostate cancer survivors. The 
e-learning series offers access to 
the latest practice-based insights 
and experiences from cancer 
survivors. The self-paced modules 
typically take an hour, but they can 
be completed in as many sittings 
as necessary, enabling health care 
providers to earn continuing edu-
cation credits at their own pace.
The E-Learning Series is a 
program of the National Cancer 
Survivorship Resource Center, a 
collaboration between the Ameri-
can Cancer Society and the GW 
Cancer Center funded through a 
five-year cooperative agreement 
with the Centers for Disease Con-
trol and Prevention.
For more information or to 
enroll in the training, visit  
cancercenter.gwu.edu/for-
health-professionals.
IN BRIEF
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sharad goyal, md, professor of radiology at the George Washington University (GW) School of Medicine and Health 
Sciences, was recently selected as a member of the NRG Oncology Developmental Therapeutics Radiation Therapy 
Subcommittee, where he will spend the next two years collaborating with fellow committee members and the Na-
tional Institutes of Health to bring new drugs to clinical trials.
“I think this is a great opportunity to give GW a place at the table with respect to working in a cooperative group,” 
said Goyal. “It raises the profile of not only radiation oncology, but also GW and the GW Cancer Center.”
NRG Oncology is one of three major cooperative groups that run clinical trials across the United States. There are sub-
committees that cover each type of cancer that NRG Oncology works on. The Developmental Therapeutics Radiation Ther-
apy Subcommittee helps to determine what molecular pathways or drug combinations may be more interesting or feasible 
in treatments. It also determines what types of tumors may benefit from those drug combinations with radiation therapy.
Lead Role in Radiation Research
the george WashiNgtoN UNi-
versity (gW) caNcer ceNter has 
assembled an internationally rec-
ognized team of experts to bring 
innovative and cutting-edge cell-
based therapy options to patients in 
the Washington, D.C., area. 
John Barrett, MD, professor of 
medicine at the GW School of Medi-
cine and Health Sciences, heads up 
the bone marrow transplant and cell 
therapies (BMT) expansion at the 
GW Cancer Center, including the 
translation of clinical research efforts 
into novel immune cell treatments. 
Barrett previously served as chief 
of the Stem Cell Transplantation 
Section of the hematology branch of 
the National Heart, Lung, and Blood 
Institute, where he began the stem 
cell transplant program. 
“Dr. Barrett is known and re-
spected throughout the international 
transplant and hematology com-
munities for his contributions as a 
physician-scientist,” said Mitchell 
Smith, MD, PhD, associate center di-
rector for clinical investigations and 
director of the Division of Cancer and 
Blood Disorders at the GW Cancer 
Center. “We know he will help us  
accomplish great things here at the  
GW Cancer Center, and are thrilled to 
have him join our leadership team.”
Barrett joins Catherine Bollard, 
MD, a pioneer and internationally 
recognized leader in the field of im-
mune cell therapies — in particular, 
novel T-cell based treatments for 
pediatric and adult patients with 
hematologic malignancies. Bollard, 
associate center director for transla-
tional research and innovation at the 
GW Cancer Center, also serves as 
the director of the Center for Cancer 
and Immunology Research at the 
Children’s Research Institute and is a 
member of the Division of Blood and 
Marrow Transplantation at Children’s 
National Health System. 
When Eduardo M. Sotomayor, 
MD, director of the GW Cancer 
Center and professor of medicine, 
joined the GW School of Medicine 
and Health Sciences in 2015, it didn’t 
take long for him to pick Bollard out 
from the crowd. “I realized then that 
together with Dr. Bollard, we would 
be able to build a world-class pro-
gram in immune cell-based thera-
pies … which is happening now,” 
said Sotomayor. Bollard, he added, 
Building a Bigger BMT Presence
IN BRIEF
played a key role in the recruitment 
of Eric Yvon, PhD, who came to GW 
from MD Anderson Cancer Center to 
direct the newly established cGMP 
Cellular Production Facility at the 
GW Cancer Center. 
“Dr. Yvon is one of the few experts 
in the nation capable of engineering 
or genetically modifying any type of 
immune cell,” said Bollard. “To build 
a premier cell therapy research and 
translational program, we recog-
nized that we needed to recruit one 
of the best.”
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iN JUNe 2018, before a room full of 
oncology experts, Robert Siegel, MD 
’77, described a new treatment de-
veloped for patients suffering from 
oropharyngeal cancer.
Siegel, associate center director 
for education, training, and network 
development at the George Wash-
ington University (GW) Cancer Cen-
ter, presented findings from a Phase 
II study during the American Society 
of Clinical Oncology’s (ASCO) Annual 
Meeting, held in Chicago. 
Oropharyngeal cancer involves 
the base of the tongue, floor of the 
mouth, and tonsils, said Siegel. It’s 
not the most common cancer, but is 
also not a rare one, he noted.
“Historically, patients who devel-
op this cancer have smoked heavily 
and consumed large amounts of 
alcohol,” he said. However, now most 
oropharyngeal tumors are a con-
sequence of human papillomavirus 
(HPV) infection; patients with HPV 
often have no history of heavy smok-
ing or alcohol abuse. HPV tumors are 
more responsive to both chemother-
apy and radiation, he added. 
The current standard treatment 
includes a combination of high-dose 
radiation plus chemotherapy. Siegel 
noted that the treatment is “80 to 90 
percent successful.” However, the 
radiation leaves patients suffering 
from myriad side effects. 
Short-term effects include dam-
age to the back of the throat that 
makes eating painful, and often cre-
ates the need for gastrostomy tubes 
to maintain adequate nutrition. In 
the long term, radiation knocks out 
the salivary glands, leaving patients 
with chronic dry mouth, which can 
lead to increased gum and dental 
disease. The radiation can also alter 
a patient’s sense of taste and cause 
chronic swallowing problems.
The investigational treatment elim-
inates the need for radiation in most 
patients. Instead, said Siegel, patients 
receive three doses of standard che-
motherapy followed by surgery.
“We found that the primary cancer 
and involved lymph nodes shrank 
dramatically with chemotherapy,” he 
said. After chemotherapy treatment, 
the cancer was removed through 
a new technique — TORS (transoral 
robotic surgery). Siegel credited 
Nader Sadeghi, MD, a former faculty 
member, for bringing the technique 
to GW. Currently that technology 
is used by GW School of Medicine 
and Health Sciences head and neck 
surgeons Arjun Joshi, MD, associate 
professor of surgery; Punam Thakkar, 
MD, assistant professor of surgery; 
and Joseph Goodman, MD, assistant 
professor of surgery.
Siegel added that throughout 
the study, patients were referred to 
standard radiation therapy if the new 
treatment wasn’t working. “We were 
doing something unique, and we 
wanted to make it as safe as possible 
for the patients,” he said.
Sixteen of the 20 patients in the 
study never needed radiation, and 
18 of 20 patients remain in remission. 
“We saw at least equal effectiveness 
in the treatment, but were cutting way 
back on the side effects,” Siegel said. 
Siegel would like to add two more 
steps in a follow-up study: using next-
generation sequencing of the tumor 
to identify which patients are at high 
risk for relapse, and incorporating ad-
ditional drugs, such as immunother-
apy drugs, to see if they would make 
the treatment even more effective. 
Robert Siegel Presents Study on 
Oropharyngeal Cancer at ASCO
Today, most oropharyngeal tumors are a 
consequence of human papillomavirus infection.
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ELIMINATING THE 
NEED FOR RADIATION
Robert Siegel, MD ’77,  described 
a new treatment developed for 
patients suffering from oropha-
ryngeal cancer during the Ameri-
can Society of Clinical Oncology’s 
Annual Meeting, held in Chicago. 
The investigational treatment, 
based on findings from a Phase 
II study, eliminates the need 
for radiation in most patients.
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alexaNdros tzatsos, md, phd,  
assistant professor of anatomy and 
cell biology at the George Wash-
ington University (GW) School of 
Medicine and Health Sciences and a 
researcher at the GW Cancer Center, 
has uncovered a connection be-
tween a specific gene, KDM6A, and 
X Marks the Spot on Pancreatic Cancer
IN BRIEF
the most aggressive form of pancre-
atic cancer.
Tzatsos’ study, published in Cancer 
Cell, found that a loss of KDM6A, an 
X chromosome-encoded histone 
demethylase, induces a histologically 
distinct subtype of pancreatic cancer 
known as “squamous-like.” The gene, 
the george WashiNgtoN UNiversity hospital, along with the GW Cancer Center, recently earned a Screening 
Center of Excellence designation from the Lung Cancer Alliance (LCA) for its ongoing commitment to responsible 
lung cancer screening. GW Hospital is one of only two hospitals in the region to hold this distinction. 
“GW Hospital and the GW Cancer Center are committed to bringing lifesaving cancer research, screenings, and 
treatment to [the] community,” said Kimberly Russo, MBA, MS, chief executive officer and managing director at GW 
Hospital, adding that low-dose CT screening for lung cancer — carried out safely, efficiently, and equitably — saves tens 
of thousands of lives a year. “We are proud to receive this recognition that reflects this ongoing and focused dedica-
tion to reducing cancer deaths across our region.”
GW Hospital has been performing low-dose CT screenings for lung cancer for four years. In that time, the hospital 
has performed more than 800 screenings and identified 320 at-risk individuals. The scan itself takes only 60 seconds 
to complete and is covered by Medicare and most insurance plans.
“Early detection of lung cancer in high-risk individuals is vital to effective treatment,” said Keith Mortman, MD, as-
sociate professor of surgery at the GW School of Medicine and Health Sciences and chief of the Division of Thoracic 
Surgery at GW Hospital. “By finding lung cancer early, we are able to work closely with our patients and multidisci-
plinary teams to create a care plan that will yield the best possible outcomes.”
Individuals may be at high risk if they meet the following criteria: they are between 55 and 77 years old; have 
smoked a pack of cigarettes or more every day for at least 30 years; and are a current smoker, or quit smoking less than 
15 years ago. It is recommended that those people have a baseline CT scan with annual follow-up scans. To schedule 
an appointment, call 1-855-495-8647 (1-855-GWLUNGS).
Lung Cancer Screening Excellence at GW
Tzatsos and his team found, is also 
frequently mutated or deleted in 
squamous-like pancreatic cancer and 
acts as a tumor suppressor. He fur-
ther determined that bromodomain 
and extra-terminal inhibitors, a class 
of small molecules now in clinical tri-
als for treating several malignancies, 
could offer a potential treatment by 
restoring cell identity and sensitizing 
tumors to current therapies.
Pancreatic cancer accounts for 
3 percent of cancers in the United 
States, and 7 percent of all cancer 
deaths. The squamous-like subtype 
of this cancer offers the worst prog-
nosis and accounts for 20–30 percent 
of pancreatic cancer cases. 
GENE CONNECTED TO  
PANCREATIC CANCER UNCOVERED 
Alexandros Tzatsos, MD, PhD, (on right) 
has uncovered a connection between a 
specific gene, KDM6A, and the most ag-
gressive form of pancreatic cancer.
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GW-SPARC Fuels 
Passion for Research
lexis deshazor-bUrNett, a risiNg JUNior at North Carolina A&T 
State University, credits the George Washington University (GW) 
Summer Program Advancing Research on Cancer (GW-SPARC) with 
opening her eyes to the myriad research paths she could follow.
Becoming a doctor was always her goal, she said, but once arriv-
ing at college, Deshazor-Burnett discovered a new passion: research.
Through GW-SPARC, she spent the summer in the lab of Alexan-
dros Tzatsos, MD, PhD, assistant professor of anatomy and cell biol-
ogy at the GW School of Medicine and Health Sciences (SMHS) and 
researcher at the GW Cancer Center. She assisted with using CRISPR, 
a revolutionary gene editing tool, to knockout KDM6A, a histone de-
methylase, in pancreatic cancer cell lines.
“I’m thinking about what I want to do, and it was great to see a lot of 
different types of people [at SMHS] with a lot of different careers,” she 
said. “It gave me a broader idea of what I could do after undergrad, 
and how I can satisfy each facet of what I want to do in my career.”
New to GW this year, the program is open to undergraduate school 
students from groups underrepresented in biomedical science and 
provides participants with a hands-on approach to cancer research. 
Students worked in laboratories focused on cancer immunology and 
immunotherapy; cancer biology, namely targeted therapies and epi-
genetics; and cancer engineering and technology.
The goals of GW-SPARC, according to Alison Hall, PhD, associate 
dean for research workforce development and professor of neurol-
ogy at SMHS, who serves as co-director of the program, are to expand 
opportunities for potential researchers and enhance diversity in the 
biomedical research community.
“GW-SPARC not only exposes participants to cutting-edge re-
search and contemporary cancer research techniques, but also fos-
ters their understanding of health disparities and the impact of cancer 
in different communities,” said Hall.
Students attended workshops on topics including sample size and 
experimental design, applying to graduate and medical school, and 
how to make a research poster. They also sat in on seminars from GW 
BY KATHERINE DVORAK
“GW-SPARC not only 
exposes participants to 
cutting-edge research 
and contemporary cancer 
research techniques, but also 
fosters their understanding 
of health disparities and 
the impact of cancer in 
different communities.”
ALISON HALL, PhD
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Cancer Center researchers, such as Katherine Chiappinelli, PhD, as-
sistant professor of microbiology, immunology, and tropical medicine 
at SMHS; Norman Lee, PhD, professor of pharmacology and physi-
ology at SMHS; and Edward Seto, PhD, associate center director for 
basic sciences at the GW Cancer Center, King Fahd Professor of Can-
cer Biology, and professor of biochemistry and molecular medicine at 
SMHS, who is also a co-director of GW-SPARC.
Ann Obi, a rising junior at Prairie View A&M University, worked in 
Chiappinelli’s lab over the summer. She first was drawn to medicine 
after visiting family in Nigeria during a summer break in high school 
and realizing the lack of health care services available there.
Obi said working in Chiappinelli’s lab was an exceptional experience.
“Everyone is nice and understanding. I don’t have a strong research 
background, so they really made an effort to make sure I understood 
what was going on. Dr. Chiappinelli was very open to answering all my 
questions,” she said. “I learned a lot.”
In addition to their time in the lab, cohort members also were re-
quired to create a poster on their research and presented their find-
ings to faculty and staff on the last day of the program.
Obi confidently presented her research to the crowd gathered in 
the Science and Engineering Hall that day, answering questions with 
a confident smile.
Before the presentation began, Hall and Seto said a few words to 
the students and attendees.
“This past week I had a chance to talk to the students, and I asked 
them what they liked about the program, and a lot of them told me ... 
they were surprised that the faculty here, despite their busy sched-
ules, were willing to sit down with them to talk with them and talk 
about their passion and how they got into science,” Seto remarked. 
“To the students, I want to say this is a mutual feeling. As a faculty 
member, I’ve learned a lot from you and benefited from the enthusi-
asm you’ve brought to this program.”
The GW Hospital Women’s Board provided partial support for 
this initiative.
A PASSION FOR RESEARCH
Becoming a doctor was always 
Lexis Deshazor-Burnett’s goal, but 
once at college, she developed a 
passion for research. The George 
Washington University Summer 
Program Advancing Research on 
Cancer and her work in the lab 
of Alexandros Tzatsos, MD, PhD, 
opened her eyes to the myriad 
research paths she could follow.
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the fUtUre of caNcer research, in the opinion of Katherine Chiappinelli, PhD, of the 
George Washington University School of Medicine and Health Sciences (SMHS), revolves 
around combining immunotherapy with other treatments. Pairing immunology with epi-
genetics, the study of changes in organisms caused by modifications to gene expression, 
she seeks to better understand the mechanisms behind epigenetic control of immune 
signaling in cancer cells. 
“The body’s own immune system is our most potent weapon against cancer cells,” 
says Chiappinelli, assistant professor of microbiology, immunology, and tropical medi-
cine at SMHS.
Although immunotherapy alone can work to fight cancer, Chiappinelli notes, it is most 
successful in patients who already have immune cells in their tumors. “Those patients in 
general respond to immune therapy, but there’s another set of patients [whose] tumor 
cells are growing very fast and there are few or no immune cells in the tumor to fight it,” 
she says. “These patients don’t do well with drugs that release the brakes on the host im-
mune system. That’s a big problem in the field.”
And it’s a problem her lab is tackling head-on. 
During a postdoctoral fellowship with Stephen Baylin, MD, at Johns Hopkins Universi-
ty, Chiappinelli found that a drug that activates tumor suppressor genes also has a strong 
immune effect. 
“When we treated cancer cells with this drug, they had more immune signaling coming 
from the tumors and more immune cells in the tumors. But we didn’t know why,” she says.
It turned out the answer was in our genomes. “Only about 2–3 percent of [human] DNA 
codes for proteins. However, about half of our DNA is repetitive sequences, and we don’t 
really know what they do,” she says. Originally, that was characterized as junk DNA, but it’s 
not junk, according to Chiappinelli. Those sequences include endogenous retroviruses, 
or dead viruses in our genetic code. Our cells turn off these viruses on purpose. But epi-
genetic drugs turn them back on.
We don’t get viral particles that can infect the cell when the retroviruses get a green 
light, Chiappinelli explains, but the viral RNA is transcribed, and that sets off an alert in 
HARNESSING THE POWER OF 
THE IMMUNE SYSTEM
BY KATHERINE DVORAK
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the cell. “The alert makes tumor cells think they are infected 
with a virus, and they die or send out signals to host immune 
cells to come and kill them,” Chiappinelli says. “So the big ef-
fect in human cancer cells and in mouse models of cancer is 
that you get more immune cells coming in to kill the tumor 
and a good anti-tumor effect, especially when you combine 
that with immune therapies.”
Chiappinelli’s interest in medical research dates back to 
high school AP biology. It was a hands-on class full of lab work 
that showed her how pursuing science could mean doing 
something different every day and enjoying the excitement of 
not knowing what would happen next. 
“That can be frustrating sometimes,” she says about the unknowns of scientific re-
search, “but I think it also makes for a really interesting career.”
She notes that she gravitated toward epigenetics, a new field during her time in gradu-
ate school, because not much was known about it then, and researchers still have much 
to learn. 
“I think, for a young person, there’s the opportunity to make important discoveries. 
It’s a field where there’s still a lot of progress to be made, in terms of both basic science 
discoveries and impact on patient care,” she adds.
Now a clinical trial Chiappinelli was involved in during her postdoctoral work at Johns 
Hopkins is underway, combining epigenetics with immune therapy. But even with the 
discoveries she’s helped make, Chiappinelli has more questions to answer: Which se-
quences do this? What things are being secreted to bring in the host immune cells? What 
are the best combinations to fully eradicate tumors?
That’s what Chiappinelli says she likes most about her work, day in and day out: “There’s 
always something new to discover.”
OUR BEST DEFENSE
Katherine Chiappinelli, PhD, says 
the body’s own immune system 
is our most potent weapon 
against cancer cells. Although 
immunotherapy alone can work 
to fight cancer, Chiappinelli 
notes, it is most successful in 
patients who already have 
immune cells in their tumors.
By pairing immunology 
with epigenetics, 
Katherine Chiappinelli, 
PhD, seeks to better 
understand the 
mechanisms behind 
epigenetic control of 
immune signaling 
in cancer cells. 
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Alumni Gift Supports Immunologic 
and Epigenetic Research
establishiNg the marleNe aNd michael 
Berman Endowed Fund for Ovarian Cancer 
Research was both personal and professional 
for Michael Berman, MD ’67, RESD ’69, a spe-
cialist in gynecologic oncology at the Univer-
sity of California, Irvine, Medical Center.
On a warm September day in 2017, Berman 
toured the George Washington University 
(GW) Cancer Center as part of Reunion Week-
end at the GW School of Medicine and Health 
Sciences (SMHS); it was on that tour that he met 
Katherine Chiappinelli, PhD, assistant profes-
sor of microbiology, immunology, and tropical 
medicine at SMHS, and spoke with her about 
her research on immunology and epigenetics.
Berman, always interested in discoveries 
that could benefit the patient population he 
has been serving for nearly 50 years, was in-
trigued; not long after talking with the young 
researcher, he wrote a $100,000 check to help 
with the growth of the Chiappinelli Lab.
“We’re on the threshold for major advances 
in immunology and immunological treatments 
of cancers, and Dr. Chiappinelli’s research is the 
kind that will lead to positive developments in 
the care of patients with ovarian cancer,” he says.
That was the professional reason for Ber-
man’s generous donation. His personal reason 
hit closer to home; Berman’s wife, Marlene, who 
passed away in 2014, had breast cancer. Later, 
all four of his daughters tested positive for the 
BRCA gene, which places them at a higher risk 
for developing breast or ovarian cancers.
“It’s a strange set of events, when you think 
about it,” Berman says. “I’m an oncologist with all 
four daughters at risk for cancer. But I think we’re 
not too far away from some major breakthroughs 
that may help patients suffering from this devas-
tating disease.” He adds that the donation was 
also made to show his appreciation for his alma 
mater, to which he feels greatly indebted.
“GW has permitted me and many others to 
have an impact on the lives of the people who 
trust us to make correct decisions and do the 
right things for them,” he says. “It’s that indebt-
edness that made me want to give back.”
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Counting on Clinical Trials
BY KATHERINE DVORAK
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iNNUmerable qUestioNs aNd coNcerNs loom after a cancer diagnosis. Among 
them: Should I participate in a clinical trial, or should I stick with the standard of care? 
Cancer treatment success rates continue to rise. The National Cancer Institute 
predicts that by 2024, almost 19 million people will live well beyond their diagnosis. 
Clinical trials play an important role in such progress.
“[They] are the mechanism by which we make progress in the treatment of cancer,” 
says Robert Siegel, MD ‘77, associate center director for education, training, and net-
work development at the George Washington University (GW) Cancer Center and 
professor of medicine at the GW School of Medicine and Health Sciences (SMHS). 
Treatments and techniques from clinical trials may be more effective than the 
current standard of care, or they may be equally effective but have fewer side ef-
fects, he explains.
Finding the right fit
Not every patient who signs up to be a part of a clinical trial will be accepted. Trials 
have certain criteria that a patient must meet to be included, measures that vary 
from trial to trial. 
A patient signing up to take part in a trial must first undergo a screening proce-
dure, which can include blood tests, physical examinations, a CAT scan, an electro-
cardiogram (EKG) test, and other tests and procedures required for the study. 
If patients have, say, an abnormal EKG, or if their medical record shows a history 
of cardiovascular disease, they may be excluded from a trial. In addition, a person 
who is confined to a bed may not be considered for participation.
Patients should be guided by their physician when considering participating in a 
trial, Siegel says. Physicians can identify the right clinical trials for their patients and 
determine whether they’re good candidates for participation. 
A BETTER OUTLOOK
Cancer treatment success rates 
continue to rise. Clinical trials 
play an important role in that 
progress, as treatments and 
techniques from clinical trials 
may be more effective than 
the current standard of care, or 
they may be equally effective 
but have fewer side effects.
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Before a patient is accepted for clinical trial, 
he or she must review and sign an informed con-
sent form. The form includes in-depth details on 
the trial, such as participation requirements, pos-
sible side effects of the treatment, and possible 
benefits. 
Once the form is signed and the patient meets 
all the eligibility criteria, therapy begins.
Participation expectations
Clinical trial volunteers will have to meet certain 
obligations during the course of the trial. Some 
of the obligations may depend on what stage of 
development the drug is in. 
“There will be questions that need to be an-
swered about how the drug behaves in the pa-
tient, what sort of side effects it has, and how 
quickly those [side effects] occur and disappear,” 
explains Richard Lush, PhD, director of the Clini-
cal Trials Office at the GW Cancer Center. “When 
those questions need to be answered earlier in 
the development, the patient might be asked to 
come back into the clinic for additional visits so 
that the patient can be checked and have labora-
tory tests done to make sure [he or she is] OK.”
In later development stages, visits may ease 
up because doctors have a better understanding 
of what to expect from the drug. 
However, generally there is a limit to the num-
ber of visits a patient needs to make. “We realize 
that people have lives they want to live even while 
on a study,” Lush says.
He adds that patients are encouraged to talk 
with the doctor and study team at any time if they 
have questions, or if they are experiencing a new 
symptom or side effect.  
A patient signing up to take part in a trial must first undergo a 
screening procedure, which can include blood tests, physical 
examinations, a CAT scan, an electrocardiogram test, and 
other tests and procedures required for the study.
Betting on benefits, but considering the risks
The benefits of a clinical trial can differ, as can any 
associated risks. 
The major benefit from a Phase I trial can be, 
simply, a new option when other treatments have 
been exhausted. Drugs administered during such 
trials could prolong a participant’s life or better 
their quality of life, says Imad Tabbara, MD, direc-
tor of the GW Medical Faculty Associates Blood 
and Bone Marrow Transplant Program and profes-
sor of medicine at SMHS. For Phase III trials, ben-
efits could include a drug with improved efficacy, 
treatment that is less toxic than the alternatives, a 
medication that’s easier to administer, or a medi-
cation that causes milder or fewer side effects. 
However, no trial is risk-free. 
“We have to be frank and tell [patients] we 
don’t know everything about this medication, 
that’s why we’re doing this [closely regulated] 
clinical trial,” Tabbara explains. “Sometimes un-
expected things happen.”
He adds that if a patient experiences unex-
pected outcomes, the trial will be halted for fur-
ther investigation into the problem. If a trial is 
halted, patients experiencing positive outcomes 
from the medication may be allowed to continue 
to receive treatment, but that’s at the discretion 
of the FDA, Tabbara says. 
Post-trial
A trial that gets through to Phase III often results 
in the treatment earning FDA approval and be-
coming a new option of care for patients across 
the United States.
The decision to participate in a trial, and 
whether it is the best option for an individual’s 
wants, needs, and health, is completely in the pa-
tient’s hands. 
But one thing is true: When patients partici-
pate and treatments are found to be effective, the 
impact reverberates far beyond the clinic’s walls.
“For the benefit of all current and future pa-
tients with cancer, we need patients to volunteer 
in trials so that we can advance the drugs that will 
improve the lives of patients,” Lush says.
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The Phases
Imad Tabbara, MD, director of the GW Medical Faculty Associates Blood and Bone 
Marrow Transplant Program, and Richard Lush, PhD, director of the Clinical Trials 
Office at the GW Cancer Center, offer their expertise and advice for understand-
ing the steps of the clinical trial process.
Phase I: The first phase of a clinical trial allows researchers to determine the ef-
ficacy of a new treatment. Phase I trials also help determine the right dose of the 
drug, demonstrate whether it has adverse side effects, and reveal any toxicity it 
might have.
The patients, says Tabbara, “have received regular treatment, or standard treat-
ment as we call it, and they didn’t respond to it, or they responded and then the 
cancer progressed. Those are usually the best candidates,” he explains.
Phase II: These trials are the second phase of drug development. A trial reaches 
Phase II once researchers have determined the effectiveness of the treatment. This 
second step establishes the response of individual agents when treating specific 
cancer types. 
These trials are often randomized, meaning trial participants receive either the 
new drug or a standard drug already in use. This enables researchers to compare 
the efficacy of the new drug to other treatments. 
Phase III: Larger randomized studies are engineered during a Phase III trial, which 
frequently is conducted by more than one institution.
Phase III trials are conducted if the treatment demonstrated sufficient activity 
in early stages of development. These trials are the last stage of testing prior to 
submitting the drug for FDA approval.
Questions to Consider
From a patient perspective, before joining a clinical trial, the most important thing 
is to get all the facts, speak with physicians, and ask, “is this what’s best for me?” 
Valuable questions to consider include: 
 > What are the potential side effects, and can they be managed easily?
 > What kinds of results have been established with this new treatment, for in-
stance from Phase I or Phase II trials? 
 > How much of a commitment will participating involve? 
 > Have there been any unexpected reactions in patients already participating? 
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UNDER ATTACK
A scanning electron micro-
graph of T-cells (blue) attacking 
a lymphoma cancer cell (pink). 
Chimeric antigen receptor 
(CAR) T-cell therapy takes T-cells 
from a patient’s bloodstream 
and reprograms them to 
recognize a specific protein 
found on lymphoma cells. The 
T-cells are reintroduced in the 
patient where the find and 
attack the lymphoma cells.
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as little as tWo decades ago early adopters of immunotherapy, looking to harness the body’s im-
mune system to fight disease, toiled in the shadow of the holy trinity of cancer therapy — surgery, che-
motherapy, and radiation therapy. Now, the immunological approach to cancer treatment has under-
gone a research renaissance. Times certainly have changed.
Following news of remarkable recoveries, this once-over-
looked avenue to a cure for cancer has captured the public’s 
imagination. Oncologists have embraced immunotherapy as 
an important advancement, and the focus now is on refining 
those therapies to increase the cure rate and ameliorate po-
tential adverse side effects.
One of the most exciting developments on the immuno-
logical front is T-cell therapies for lymphoma. T-cells are a type 
of lymphocyte produced or processed by the thymus gland 
(the T comes from thymus) that actively participate in the im-
mune response. Typically, the most widely reported among 
these new treatments is CD19 CAR T-cell therapy. Doctors at-
tach chimeric antigen receptors (CAR) to T-cells and reintro-
duce them in the patient to seek out cancer cells and produce 
chemical compounds that destroy them. 
A research team led by Catherine Bollard, MD, associate 
center director for translational research and innovation at 
the George Washington University (GW) Cancer Center, has 
developed a different therapeutic approach called TAA-T, 
which is a multi-antigen specific T-cell product that may be su-
perior in many ways to the recently FDA-approved CD19 CAR 
T-cell therapy. 
“If you’ve got a tumor cell, there are several ways to kill it,” says Bollard, who also serves as profes-
sor of pediatrics at the GW School of Medicine and Health Sciences (SMHS) and director of the Center 
for Cancer and Immunology Research at Children’s Research Institute, part of Children’s National 
Health System (Children’s National). The CD19 CAR T-cell technique, she explains, involves geneti-
cally engineering a T-cell — adding an artificial receptor — so that it recognizes and kills the tumor.
An Inside Job 
BY STEVE GOLDSTEIN
IMMUNOTHERAPY LOOKS TO HARNESS THE BODY’S  
DEFENSE AND CURE CANCER FROM THE INSIDE OUT
A LEADER IN IMMUNOTHERAPY
Catherine Bollard, MD, is the associ-
ate center director for translational 
research and innovation at the George 
Washington University Cancer Center.
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TAA-T requires no genetic engineering. Tu-
mor-killing T-cells, present naturally in everyone, 
are harvested from the patient and fed with cy-
tokines or other chemicals in the lab where tech-
nicians grow their numbers to millions. They are 
then re-infused into the patient. Bollard says the 
entire process used to take three to six months, 
which dimmed its luster. Now it can be complet-
ed in less than two weeks, “so it’s a much more 
nimble process,” she notes.
Genetic modification, on the other hand, is 
expensive and heavily regulated and thus a cum-
bersome process. TAA-T has none of these disad-
vantages. Moreover, CAR T is limited to recogniz-
ing proteins on the surface of the tumor cells, and 
that is very restricting, Bollard explains. “There 
are only a limited number of proteins on the sur-
face of tumors (or ‘extracellular antigens’) you can 
target with CAR T,” she says, “whereas our TAA-T 
can target what is known as intracellular antigens 
— proteins within the tumor cells — and there are 
many more of these cancer-specific proteins that 
can be targeted. In addition, because CAR T tar-
gets only one antigen, the patient can develop a 
resistance to the therapy.”
The minimal toxicity of TAA-T is perhaps its most 
significant advantage. Patients undergoing CD19 
CAR T-cell therapy sometimes experience cyto-
kine release syndrome, or CRS, which is caused 
by a large, rapid release of cytokines and cellular 
by-products into the bloodstream when the can-
cer cells are destroyed. Symptoms can vary from 
the relatively mild — fever, nausea, headache, rash, 
rapid heartbeat, low blood pressure, and trouble 
breathing — to the more severe. According to Bol-
lard, CD19 CAR T-cell therapy is associated with 
“appreciable toxicities including neurotoxicity and, 
in some cases, death.”
In Phase I clinical trials 
with Bollard’s TAA-T therapy, 
researchers are now seeing 
75 percent efficacy, espe-
cially in acute myeloid leu-
kemia, which the trials with 
CAR T have thus far been un-
able to achieve. “We’re just beginning to increase 
the number of patients [in the trials], both adult 
and pediatric,” says Bollard. “We were initially col-
laborating with [Johns] Hopkins because the pro-
gram at GW wasn’t up and running, but with Ki-
eron’s arrival at GW we are now ready to move this 
therapy forward at GW for the treatment of other 
forms of lymphoma and even multiple myeloma.”
Kieron is Kieron Dunleavy, MD, director of the 
lymphoma program and professor of medicine 
at SMHS. “We are excited for Kieron to lead the 
novel T-cell therapy studies at GW,” Bollard says. 
“We obviously see GW as a huge player in this 
because of Eduardo [Sotomayor, MD, director of 
the GW Cancer Center and professor of medicine 
at SMHS], Kieron, and Mitch [Smith, MD, PhD, as-
sociate center director for clinical investigations 
at GW Cancer Center], who are all internationally 
renowned lymphoma physicians.”
the coNcept of eNgiNeeriNg chimeric antigen receptors dates back about 20 years, and it has 
been touted as a treatment for a range of cancers. Two CAR T-cell therapies were approved by the 
FDA in 2017, and since then the number of immunotherapy trials has grown. 
Cytokine Release Syndrome, or CRS, occurs after CAR T-cell treatment. Symptoms such as fever, 
nausea, headache, or trouble breathing can range from mild to severe or even life-threatening. Ac-
cording to the National Cancer Institute, the more effective the CAR T-cell treatment is, the more 
likely a patient is to experience CRS because the therapy has destroyed so many cancer cells the 
body is littered with cellular debris. The rapid release of cytokines into the blood from the immuno-
therapy can send the immune system into a tailspin. 
Chimeric Antigen Receptor (CAR) T-cell Therapy
A STRONG TEAM
Catherine Bollard, 
MD, (center), leads a 
team of internationally 
renowned researchers 
the GW Cancer Center. 
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A research team led by Catherine Bollard, MD, 
has developed a therapeutic approach called 
TAA-T, which may be superior in many ways to the 
recently FDA-approved CD19 CAR T-cell therapy. 
hUmaNs’ immUNe system featUres 
a variety of white blood cells — includ-
ing macrophages, dendritic cells, and 
several types of lymphocytes — each 
with a different method for protecting 
the body from foreign invasion or dis-
ease. These types of white blood cells 
circulate to every part of the body, 
providing protection from cancer and 
other diseases.
 > Macrophages are white blood cells 
that swallow and digest foreign 
particles and signal other immune 
system cells to go into action.
 > Dendritic cells present the foreign 
cells to the immune system.
 > Lymphocytes include B-cells, T-cells, 
and natural killer cells (NK) cells:
 > B-cells make antibodies that 
tag foreign or abnormal cells 
so other parts of the immune 
system can destroy them.
 > T-cells directly attack cancer 
cells and signal other immune 
system cells to defend the body.
 > NK cells find, bind to, and kill 
foreign invaders or damaged 
cells in the body.
Dunleavy came to GW in May 2017 after nearly 
15 years at the National Institutes of Health work-
ing on lymphoma therapies and trials. “My goal 
is to improve the cure rate for the most common 
form of lymphoma, called diffuse large B-cell 
lymphoma. There are lots of exciting therapies 
in development, and they are really changing the 
face of lymphoma,” he says.
Because all cancer tumors have proteins on 
their surface, Bollard’s lab “trains” the T-cells by 
loading “trainer cells,” called antigen-presenting 
cells, with pieces of the proteins (peptides) that are 
expressed by the tumor cell. Then the researchers 
mix these peptide-loaded training cells with T-cells 
from the patient or a healthy donor. The T-cells are 
stimulated by the tumor peptides to reproduce in 
the laboratory, growing to large enough numbers 
that they can then be infused back into the patient. 
“These [enhanced] T-cells,” explains Bollard, “will 
then kill the tumor target, get stimulated, and con-
tinue to replicate in the patient.
“In some ways it’s like a cancer vaccine,” she 
explains, “but you’re doing the job of the vaccines 
in the lab.”
Adult trials began in the fall of 2016, and pediatric 
patients joined the study in April 2017. “We started 
with patients who’d had a bone marrow transplant,” 
says Bollard. “What we want to do with Kieron is to 
incorporate patients who are ineligible for trans-
plants, or who weren’t going to have a transplant, 
and combine [TAA-T] with other immunotherapies 
— for instance, adding checkpoint inhibitors.”
Checkpoint inhibitors are molecules that 
block immune checkpoints, which are receptors 
or ligands that modulate the immune response. 
In many cancers, tumor cells express these check-
points to “put the brakes on” the immune system. 
Blocking the immune checkpoint thus releases 
the brakes.
“Tumors are clever,” Bollard says with a wry 
grin, “and they try to resist attack from the im-
mune system. We’ve always treated cancer with 
different drugs. My feeling now is we should treat 
cancer with different immune therapies. And as 
long as you don’t increase toxicity to crazy lev-
els, it’s really enhancing the immune therapy to 
increase efficacy.”
Arming the Immune System
Bollard opens her computer and pulls up a 
graphic that displays the huge number of immu-
notherapy projects going on around the world. 
It’s nearly as vast and dense as a chart of stars. For 
years, she explains, oncologists have thought of 
cancer as a disease that needed to be treated by 
drugs. “Those of us who were proponents of the 
immune system being our best defense against 
cancer were looked at with a pretty dim view,” 
she says.
“Whether or not these cells are the be-all and 
end-all, what this means is that the community is 
now understanding that the immune system is re-
ally our first line of defense against cancer,” says 
Bollard. “We should be harnessing it early in the 
disease process and not waiting until we’ve killed 
off the immune system with multiple lines of che-
motherapy and/or radiation, and then trying to 
get the immune system to help us.”
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gaziNg at the icoNic 19th-ceNtUry Japanese woodcut known as “The Great Wave 
off Kanagawa,” one would hardly suspect it contains a key to a medical breakthrough. 
Yet the pigment in the artwork has opened a new perspective in the treatment of juve-
nile cancer.
The artist, Hokusai, used Prussian blue pigment 
in his masterpiece. By combining the same deep 
blue nanoparticles with an immunotherapy class 
called checkpoint inhibitors, researchers have 
engineered a “nanoimmunotherapy” for treating 
neuroblastoma, a leading cause of cancer-related 
death among children. The nanoparticles are ad-
ministered to neuroblastoma tumors, where they 
are activated with near infrared light. The light ac-
tivation causes the nanoparticles to heat and de-
stroy tumor tissue and elicit a robust anti-tumor re-
sponse from the immune system. These anti-tumor 
effects are made more potent by the administra-
tion of the checkpoint inhibitor treatment.
Nanoimmunology, as the field is called, is re-
ally the synthesis of nanotechnology and immuno-
therapy — a marriage of engineering and medicine. 
Nano is the science of tiny, explains Rohan Fer-
nandes, PhD, the leader of a team in the George 
Washington University (GW) Cancer Center, inte-
grating nanoscience with the immune response. 
“Nanoimmunology takes these tiny particles that 
can interact with the immune system to elicit a ro-
bust response for any therapeutic purpose, whether it be infections or cancer,” says 
Fernandes, who also serves as assistant professor of medicine at the GW School of 
Medicine and Health Sciences (SMHS).
BY STEVE GOLDSTEIN
R I D I N G  A  W AV E  O F
 N A
N O
T E C H N O L O G Y
THE SYNTHESIS OF NANOTECHNOLOGY 
AND IMMUNOTHERAPY
Rohan Fernandes, PhD, is the leader 
of a team in the George Washington 
University Cancer Center integrating 
nanoscience with the immune response.
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How small are nanopar-
ticles? The particles are 
measured in nanometers, 
a measure equal to a bil-
lionth of a meter. Nano-
technology is concerned 
with the use and control 
of structures that range 
from one to 100 nanome-
ters in size.
Fernandes, 39, is an 
engineer by training who 
earned his PhD in bioen-
gineering from the Uni-
versity of Maryland. Af-
ter a fellowship at Johns 
Hopkins University, he came under the mentorship 
of Catherine Bollard, MD, associate center director 
for translational research and innovation at the GW 
Cancer Center, and professor of pediatrics and of 
microbiology, immunology, and tropical medicine 
at SMHS. Fernandes joined the GW Cancer Cen-
ter in December 2017. “I thought my field [of nano-
technology] would be useful for immunology,” says 
Fernandes, adding that the science “is actually the 
dynamic interplay between the nano world and the 
immunotherapy world.”
Over his career, Fernandes saw a lot of neuroblas-
tomas. As a grad student, he’d become familiar with 
the story of Alexandra “Alex” Scott, who, after being 
diagnosed with neuroblastoma, set up a front-yard lemonade stand to raise money for 
research. A year after Alex died in 2004, her parents started the Alex’s Lemonade Stand 
Foundation. “Alex’s courageous struggle was one of the motivations to undertake re-
search that is more translational,” he explains. In January 2018, Fernandes and his team 
received more than $700,000 from the foundation for neuroblastoma research.
What are checkpoint inhibitors? They are molecules that block immune checkpoints, 
which are receptors or ligands that modulate the immune response. In many cancers, 
tumor cells express these checkpoints to “hide” from the immune system. Blocking the 
immune checkpoint “releases the brakes” on the immune system.
“We try to break up the tumor so that the tumor cells are killed by the nanoparticles, 
and in doing so we present the dying tumor cells to the immune system,” Fernandes 
explains. “Simultaneously, we take the brakes off the immune system, which recognizes 
the tumor cells, so the immune system can go after what we want.”
Nanoparticles are made of metallic polymers that absorb the near infrared light and 
dissipate the resulting energy into heat through a process known as photothermal con-
version. This process helps limit the effect on healthy cells. “We get the majority of the 
tumor, but there will be collateral damage to some surrounding tissue,” says Fernandes.
In a newly published paper by the team led by Fernandes, researchers describe a 
“We try to break up the tumor 
so that the tumor cells are killed 
by the nanoparticles, and in 
doing so we present the dying 
tumor cells to the immune 
system. Simultaneously, 
we take the brakes off the 
immune system, which 
recognizes the tumor cells, 
so the immune system can 
go after what we want.”
ROHAN FERNANDES, PhD
AN ENGINEER BY TRAINING
Rohan Fernandes, PhD is an engineer 
by training. He earned his PhD in 
bioengineering from the University of 
Maryland. After a fellowship at Johns 
Hopkins University, came under the 
mentorship of Catherine Bollard, 
MD, associate center director for 
translational research and innovation 
at GW Cancer Center, and professor 
of pediatrics and of microbiology, 
immunology, and tropical medicine 
at SMHS. Fernandes joined the GW 
Cancer Center in December 2017. 
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technique that uses temperature control to turn immunotherapy on or off in a tumor 
environment.
“When temperatures are at 60 degrees, the tumors are not immunogenic, meaning 
that the immune response cannot recognize the nanoparticles,” reports Juliana Caro-
Mejia, a University of Maryland bioengineering PhD candidate. “With the heat varying 
in a window of 60 to 65 degrees, the tumor cells are expressing immunogenic markers. 
Finding this window was very exciting!”
The process has already been tested on mice. The results to date indicate that treat-
ment can boost long-term survival rates by 50 percent in the treated animals. Testing 
on humans is not imminent, however. “The Food and Drug Administration is very strin-
gent about allowing pediatric trials,” says Fernandes. His goal is to get into clinical trials 
within the decade. 
Nanotechnology is concerned 
with the use and control of 
structures that range from one 
to 100 nanometers in size.
the george WashiNgtoN UNiversity (gW) Cancer Center offers its investigators a 
wealth of state-of-the-art infrastructure for research and development, with additional re-
sources available through a partnership with the Clinical and Translational Science Insti-
tute at Children’s National (CTSI-CN). Much of the infrastructure to support GW research 
is organized in scientific cores offering a range of services, including the Nanofabrication 
and Imaging Center, the Research Pathology Laboratory, the Flow Cytometry Core Facil-
ity, the GW Biorepository, the Biostatistics Center, and the Cancer Informatics Core.
The Nanofabrication and Imaging Center includes a class 100 cleanroom equipped 
with a full spectrum of nanotechnology equipment, in addition to a microimaging suite 
with ultra-high-resolution lithography and scanning electron microscopy allowing visu-
alization of structures at the atomic level.
A Research Pathology Core provides research services for both human and animal 
tissues, including tissue processing, embedding, sectioning, routine and specialized 
sample staining, frozen sections, and immunohistochemistry.
The Flow Cytometry Core Facility provides sophisticated cell sorting and cell analy-
sis experiments, as well as services in data analysis, instrument training and cytometry 
education, and cytometry data.
The GW Biorepository is a comprehensive, state-of-the-art resource that features 
more than 100,000 biospecimens and clinical data related to HIV malignancies, neurol-
ogy, and cancer cases.
The Biostatistics Center serves as the coordinating center for large scale, multi-center 
clinical trials and epidemiologic studies, offering statistical leadership for the design, 
execution, and analysis of multi-center clinical trials and epidemiologic investigations.
GW Cancer Center researchers also have access to GW’s Cancer Informatics Core 
pilot project, which provides collaborative informatics support for cancer research 
through guidance for software use and by acting as liaison for various next-generation 
sequencing data services.
At the Core
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The George Washington University Cancer Center, with support provided by the Dr. Cyrus and Myrtle 
Katzen Cancer Research Center (Katzen Center), offers a wide variety of holistic and wellness services 
for cancer patients and their families. These groups are free of charge and open to the community.
SUPPORT GROUPS
THE GW MEDICAL  
FACULTY ASSOCIATES 
(GW MFA)
2150 Pennsylvania Ave., NW
Washington, D.C. 20037
ACTIVE TREATMENT
(all cancers)
Open to patients currently in treatment. 
Registration required.
Second and fourth Wednesday
of each month, 12:30–1:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
ADVANCED BREAST
CANCER GROUP
Open to patients with stage IV 
breast cancer. Registration required.
Fourth Tuesday of each month,
Noon–1 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
BRAIN TUMOR SUPPORT GROUP
Open to brain tumor patients and 
survivors and caregivers.
Registration required.
First Tuesday of each month,
6–7:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Alicia Gray, LGSW
algray@mfa.gwu.edu
202-677-6597
CAREGIVERS’ SUPPORT GROUP
Open to caregivers of those diagnosed 
with cancer to share common concerns, 
give and receive advice, and learn 
coping skills. Registration required.
Third Tuesday of each month, 
12:30–1:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Alicia Gray, LGSW
algray@mfa.gwu.edu
202-677-6597
GENTLE YOGA
This group introduces patients 
and caregivers to the physical and 
emotional benefits of yoga.
Tuesdays, 4–5 p.m.
GW Marvin Center,
Fifth floor activities room
800 21st St., NW
Facilitator: Yael Flusberg
eruiz@mfa.gwu.edu
202-677-6228
HEAD AND NECK CANCER GROUP
For head and neck cancer patients 
and survivors, and their caregivers. 
Registration required.
First Tuesday of each month, 
12:30–1:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Alicia Gray, LGSW
algray@mfa.gwu.edu
202-677-6597
KIDS’ CLUB
For families with kids (ages 6–12)
in which a parent or sibling is in 
treatment or is a survivor.
Fourth Wednesday of each month,
6–7:30 p.m.
Smith Center for Healing and the Arts
1632 U St., NW
Facilitators: Erin Price and  
Lauren Broschak, LGSW
202-483-8600
MULTIPLE MYELOMA GROUP
This group is open to multiple myeloma 
patients and survivors, and their 
caregivers. Registration required.
Third Tuesday of each month,
5:30–6:30 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Alicia Gray, LGSW
algray@mfa.gwu.edu
202-677-6597
NUTRITION CLUB
First Monday of each month, Noon–1 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Jennifer Leon
202-741-6489
PROSTATE CANCER
EDUCATIONAL GROUP
The prostate cancer educational group 
is open to patients and survivors, and 
their caregivers. Registration required.
Second Tuesday of each month,
6–7 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Lauren Broschak, LGSW
lbroschak@mfa.gwu.edu
202-677-6229
SURVIVORSHIP SERIES
An educational series featuring a 
different speaker each month.
Second Thursday of each month,
11:45 a.m.–12:45 p.m.
GW Cancer Center Board Room
MFA, first floor, 1-402
Facilitator: Alicia Gray, LGSW
algray@mfa.gwu.edu
202-677-6597
YOUNG ADULT GROUP
Young adults (19– 39 years of age)  
who are currently in treatment or  
are cancer survivors.
Third Sunday of each month,
5–6:30 p.m.
Smith Center for Healing and the Arts
1632 U St., NW
Facilitator: Jennifer Bires
202-483-8600
Parking is validated for all groups 
at the GW Cancer Center. For 
more information about upcoming 
support groups and events, visit
cancercenter.gwu.edu/for-patients/
patientcaregiver-support.
Executive 
Committee
Jeffrey S. Akman, MD ’81, RESD 
’85, vice president for health affairs, 
Walter A. Bloedorn Professor of 
Administrative Medicine, and 
dean, the George Washington 
University (GW) School of 
Medicine and Health Sciences
Kimberly Russo, MBA, 
MS, CEO and managing 
director of GW Hospital
Robert E. Kelly, MD, CEO of 
the clinical enterprise, GW 
Medical Faculty Associates
External 
Advisory Board
Edward Benz, MD, former 
director, Dana Farber Cancer 
Institute / Harvard University
William Dalton, MD, PhD, former 
director, H. Lee Moffitt Cancer Center
Robert DiPaola, MD, dean, 
University of Kentucky 
College of Medicine
Stan Gerson, MD, director, Case 
Comprehensive Cancer Center / 
Case Western Reserve University
Stephen B. Gruber, MD, PhD, 
MPH, director of the University 
of Southern California Norris 
Comprehensive Cancer Center
Helen Heslop, MD, PhD, 
director, Center for Cell and Gene 
Therapy, Baylor University
Marcy Waldinger, MS, former 
chief administrative officer, 
University of Michigan
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A TEAM Approach 
to Cancer Care
represeNtatives from 24 mUltidis-
cipliNary health care teams nation-
wide joined the George Washington 
University (GW) Cancer Center for its 
inaugural TEAM (Together, Equitable, 
Accessible, Meaningful) Training 
program intended to help health care 
organizations implement quality im-
provements in patient-provider com-
munication, cultural sensitivity, health 
literacy, and shared decision-making.
Leading experts discussed ways to 
support health equity, patient engage-
ment, and culturally affirming cancer 
care. Keynote speaker Camara Jones, 
MD, MPH, PhD, past president of the 
American Public Health Association 
and senior fellow at the Satcher Health 
Leadership Institute, Morehouse School 
of Medicine, discussed the impact 
that social determinants of health and 
health equity can have on patient out-
comes. Fellow speaker Tamika Felder, 
founder of Cervivor, a nonprofit cervical 
cancer awareness and support orga-
nization, stressed the need to support 
patient engagement in clinical care.
“When we were awarded funding 
from the Pfizer Foundation in 2016 to 
develop a project focused on reduc-
ing cancer disparities, we conducted 
extensive formative research with pa-
tients and providers to find out where 
the gaps [were] when it comes to 
patient-provider communication,” said 
Mandi Pratt-Chapman, MA, associate 
center director for patient-centered 
initiatives and health equity at the GW 
Cancer Center. “This training is the 
culmination of many months of learn-
ing for these teams, and we’re hopeful 
that the insights they gain will result in 
real positive changes as they return to 
their home institutions.”
Before arriving, participants 
completed an online course covering 
topics such as engaging patients and 
their loved ones in shared decision-
making, increasing minority patient 
representation in cancer research, 
supporting patient self-advocacy, and 
enacting culture change to support 
the provision of culturally affirming 
care. The TEAM training is part of a 
multiphase project that includes de-
velopment of patient resources. 
“The GW Cancer Center is com-
mitted to advancing the health of all 
patients,” said Eduardo M. Sotomayor, 
MD, director of the GW Cancer Cen-
ter. “Programs like TEAM represent a 
significant opportunity for institutions 
across the country to address inequi-
ties in health care that continue to 
challenge racial, ethnic, sexual, and 
gender minority cancer patients.”
To learn more, visit bit.ly/
AboutTEAMProject.
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